18534250

Source:http://linkedlifedata.com/resource/pubmed/id/18534250

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0036525, umls-concept:C0045093, umls-concept:C0246415, umls-concept:C0280631, umls-concept:C0282460, umls-concept:C1512288, umls-concept:C1521828, umls-concept:C1522484, umls-concept:C1708063
pubmed:issue	3
pubmed:dateCreated	2008-6-6
pubmed:abstractText	Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 37517, http://linkedlifedata.com/resource/pubmed/grant/CA27469
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-10479491, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-10955863, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-11230465, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-11748990, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-11872347, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-12065559, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-12694653, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-14766260, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-15140550, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-1536229, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-15888762, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-16110008, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-16134177, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-16496406, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-16568459, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-17221305, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-17306350, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-17409898, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-17442230, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-17602081, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-1874603, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-1941054, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-1999720, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-2154921, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-2208147, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-3690545, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-6344983, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-7602342, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-8751554, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-8898180, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-9537200, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-9740703, http://linkedlifedata.com/resource/pubmed/commentcorrection/18534250-9819829
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0365304
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	1095-6859
pubmed:author	pubmed-author:BlessingJohn AJA, pubmed-author:HensleyMartee LML, pubmed-author:MannelRobertR, pubmed-author:RosePeter GPG
pubmed:issnType	Electronic
pubmed:volume	109
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	329-34
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:18534250-Adult, pubmed-meshheading:18534250-Aged, pubmed-meshheading:18534250-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18534250-Deoxycytidine, pubmed-meshheading:18534250-Disease-Free Survival, pubmed-meshheading:18534250-Female, pubmed-meshheading:18534250-Humans, pubmed-meshheading:18534250-Leiomyosarcoma, pubmed-meshheading:18534250-Middle Aged, pubmed-meshheading:18534250-Taxoids, pubmed-meshheading:18534250-Uterine Neoplasms
pubmed:year	2008
pubmed:articleTitle	Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
pubmed:affiliation	Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. gynbreast@mskcc.org
pubmed:publicationType	Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, N.I.H., Extramural